The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

Archive ouverte

Berlanga, Pablo | Pierron, Gaëlle | Lacroix, Ludovic | Chicard, Mathieu | Beaumais, Tiphaine Adam, De | Marchais, Antonin | Harttrampf, Anne C. | Iddir, Yasmine | Larive, Alicia | Fernandez, Aroa Soriano | Hezam, Imene | Chevassus, Cecile | Bernard, Virginie | Cotteret, Sophie | Scoazec, Jean-Yves | Gauthier, Arnaud | Abbou, Samuel | Corradini, Nadège | André, Nicolas | Aerts, Isabelle | Thebaud, Estelle | Casanova, Michela | Owens, Cormac | Michiels, Stefan | Hladun-Alvaro, Raquel | Delattre, Olivier | Vassal, Gilles | Schleiermacher, Gudrun | Geoerger, Birgit

Edité par CCSD ; American Association for Cancer Research -

International audience. MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered ``ready for routine use.'' Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies-56% of them within early clinical trials-mainly in the AcSe-ESMART platform trial (NCT02813135). Overall, matched treatment resulted in a 17% objective response rate, and of those patients with ready for routine use alterations, it was 38%. In patients with extracerebral tumors, 76% of actionable alterations detected in tumor tissue were also identified in circulating cell-free DNA (cfDNA).

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion